XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.23.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and six-month periods ended June 30, 2023 and July 1, 2022 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.
| Biotechnology |  | Life Sciences |  | Diagnostics |  | Environmental & Applied Solutions |  | Total
For the Three-Month Period Ended June 30, 2023: |  |  |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |  |  |
North America(a) | $ | 611 |  |  | $ | 757 |  |  | $ | 982 |  |  | $ | 577 |  |  | $ | 2,927 |
Western Europe | 684 |  |  | 375 |  |  | 365 |  |  | 284 |  |  | 1,708 |
Other developed markets(b) | 72 |  |  | 124 |  |  | 100 |  |  | 31 |  |  | 327 |
High-growth markets(c) | 518 |  |  | 540 |  |  | 784 |  |  | 353 |  |  | 2,195 |
Total | $ | 1,885 |  |  | $ | 1,796 |  |  | $ | 2,231 |  |  | $ | 1,245 |  |  | $ | 7,157 |
Revenue type: |  |  |  |  |  |  |  |  |
Recurring | $ | 1,534 |  |  | $ | 1,104 |  |  | $ | 1,958 |  |  | $ | 742 |  |  | $ | 5,338 |
Nonrecurring | 351 |  |  | 692 |  |  | 273 |  |  | 503 |  |  | 1,819 |
Total | $ | 1,885 |  |  | $ | 1,796 |  |  | $ | 2,231 |  |  | $ | 1,245 |  |  | $ | 7,157 |
For the Three-Month Period Ended July 1, 2022: |  |  |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |  |  |
North America(a) | $ | 798 |  |  | $ | 778 |  |  | $ | 1,235 |  |  | $ | 571 |  |  | $ | 3,382 |
Western Europe | 632 |  |  | 340 |  |  | 453 |  |  | 266 |  |  | 1,691 |
Other developed markets(b) | 88 |  |  | 111 |  |  | 115 |  |  | 32 |  |  | 346 |
High-growth markets(c) | 748 |  |  | 472 |  |  | 758 |  |  | 354 |  |  | 2,332 |
Total | $ | 2,266 |  |  | $ | 1,701 |  |  | $ | 2,561 |  |  | $ | 1,223 |  |  | $ | 7,751 |
Revenue type: |  |  |  |  |  |  |  |  |
Recurring | $ | 1,804 |  |  | $ | 1,068 |  |  | $ | 2,301 |  |  | $ | 719 |  |  | $ | 5,892 |
Nonrecurring | 462 |  |  | 633 |  |  | 260 |  |  | 504 |  |  | 1,859 |
Total | $ | 2,266 |  |  | $ | 1,701 |  |  | $ | 2,561 |  |  | $ | 1,223 |  |  | $ | 7,751 |
| Biotechnology |  | Life Sciences |  | Diagnostics |  | Environmental & Applied Solutions |  | Total
For the Six-Month Period Ended June 30, 2023: |  |  |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |  |  |
North America(a) | $ | 1,229 |  |  | $ | 1,465 |  |  | $ | 2,106 |  |  | $ | 1,149 |  |  | $ | 5,949 |
Western Europe | 1,331 |  |  | 739 |  |  | 785 |  |  | 561 |  |  | 3,416 |
Other developed markets(b) | 151 |  |  | 252 |  |  | 217 |  |  | 60 |  |  | 680 |
High-growth markets(c) | 1,038 |  |  | 1,049 |  |  | 1,499 |  |  | 693 |  |  | 4,279 |
Total | $ | 3,749 |  |  | $ | 3,505 |  |  | $ | 4,607 |  |  | $ | 2,463 |  |  | $ | 14,324 |
Revenue type: |  |  |  |  |  |  |  |  |
Recurring | $ | 3,045 |  |  | $ | 2,143 |  |  | $ | 4,070 |  |  | $ | 1,466 |  |  | $ | 10,724 |
Nonrecurring | 704 |  |  | 1,362 |  |  | 537 |  |  | 997 |  |  | 3,600 |
Total | $ | 3,749 |  |  | $ | 3,505 |  |  | $ | 4,607 |  |  | $ | 2,463 |  |  | $ | 14,324 |
For the Six-Month Period Ended July 1, 2022: |  |  |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |  |  |
North America(a) | $ | 1,580 |  |  | $ | 1,516 |  |  | $ | 2,541 |  |  | $ | 1,099 |  |  | $ | 6,736 |
Western Europe | 1,339 |  |  | 668 |  |  | 977 |  |  | 535 |  |  | 3,519 |
Other developed markets(b) | 173 |  |  | 248 |  |  | 239 |  |  | 64 |  |  | 724 |
High-growth markets(c) | 1,390 |  |  | 935 |  |  | 1,448 |  |  | 687 |  |  | 4,460 |
Total | $ | 4,482 |  |  | $ | 3,367 |  |  | $ | 5,205 |  |  | $ | 2,385 |  |  | $ | 15,439 |
Revenue type: |  |  |  |  |  |  |  |  |
Recurring | $ | 3,605 |  |  | $ | 2,105 |  |  | $ | 4,671 |  |  | $ | 1,409 |  |  | $ | 11,790 |
Nonrecurring | 877 |  |  | 1,262 |  |  | 534 |  |  | 976 |  |  | 3,649 |
Total | $ | 4,482 |  |  | $ | 3,367 |  |  | $ | 5,205 |  |  | $ | 2,385 |  |  | $ | 15,439 |
(a) The Company defines North America as the United States and Canada. (b) The Company defines other developed markets as Japan, Australia and New Zealand. (c) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration